Welcome to our dedicated page for Atrium Therapeutics SEC filings (Ticker: RNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Atrium Therapeutics filings document the corporate transition that created the current RNA issuer and the related Avidity Biosciences merger, separation and listing records. The filing set includes 8-K material-event reports, shareholder voting disclosures, separation and merger agreement records, capital-structure information and a Form 25 covering removal of Avidity common stock from Nasdaq listing and registration.
Regulatory disclosures tied to the symbol also cover governance matters, operating and financial results, clinical or regulatory updates and security-structure information. As an independent biopharmaceutical company, Atrium's filings center on its RNA therapeutics platform, precision cardiology pipeline, collaboration economics, equity compensation and public-company reporting obligations.
Avidity Biosciences, Inc. reported that Chief Program Officer Kathleen P. Gallagher disposed of stock options and common shares in connection with the company’s merger with Novartis AG.
The filing shows multiple stock option awards labeled as “Stock Option (Right to Buy)” and 80,303 shares of Common Stock, including shares underlying previously reported restricted stock units, were transferred back to the issuer under the Agreement and Plan of Merger. According to the terms, the options were exchanged for cash equal to the merger consideration of $72.00 per share minus their exercise price, reflecting a cash-out as part of the merger close rather than open-market sales.
Avidity Biosciences director Noreen Henig reported multiple dispositions of stock options and common stock of Avidity Biosciences. The securities were surrendered to the company in connection with a planned merger under an Agreement and Plan of Merger with Novartis AG. According to the filing, the reported options were canceled under the merger terms in exchange for cash equal to the excess of the merger consideration of $72.00 over each option’s exercise price, leaving no remaining holdings from these awards.
Avidity Biosciences director Jean Jinsun Kim reported the disposition of stock options and common shares to the company in connection with its merger with Novartis. The filing shows multiple stock option awards and common stock, including shares from previously reported restricted stock units, were surrendered as part of the transaction.
According to the merger agreement among Novartis AG, Ajax Acquisition Sub, Inc., and Avidity Biosciences, the reported options were exchanged for cash equal to the merger consideration of $72.00 per share minus the applicable exercise price, rather than being sold in the open market.
Avidity Biosciences director Arthur A. Levin reported the cash-out of his equity in connection with the company’s merger with Novartis AG. On February 27, 2026, multiple stock options and shares of common stock were disposed of to the issuer under an Agreement and Plan of Merger dated October 25, 2025.
The filing shows dispositions of stock options and common stock, including 16,562 shares of common stock held directly and 131,372 shares held indirectly by a family trust. The footnotes state that options were cancelled in exchange for cash equal to the excess of the $72.00 per-share merger consideration over their exercise prices, and that common stock (including shares issuable from previously reported restricted stock units) was disposed of pursuant to the merger terms.
Avidity Biosciences director Edward M. Kaye, MD reported multiple dispositions of stock options and common shares to the company in connection with its acquisition by Novartis. The filing shows stock options and common stock were transferred to the issuer under a merger agreement with Novartis and Ajax Acquisition Sub.
According to the footnotes, the common shares (including those underlying previously reported restricted stock units) were disposed of pursuant to the Agreement and Plan of Merger dated October 25, 2025. The reported stock options were cashed out for a payment equal to the excess of the merger consideration of $72.00 per share over their exercise prices.
Avidity Biosciences director Carsten Boess reported dispositions of stock options and common shares in connection with the company’s acquisition by Novartis. Several “Stock Option (Right to Buy)” awards and 6,692 shares of common stock were transferred to the issuer under the merger agreement.
The options were canceled in exchange for a cash payment equal to the excess of the merger consideration of $72.00 per share over each option’s exercise price, reflecting cash-out treatment rather than open-market sales.
Avidity Biosciences Chief Commercial Officer Eric Mosbrooker reported the disposition of stock options and common shares in connection with the company’s merger with Novartis. The filing shows 177,188 and 50,000 stock options and 79,413 shares of common stock were transferred to the issuer.
According to the merger agreement dated October 25, 2025, the common stock, including shares underlying previously reported restricted stock units, was disposed of as part of the transaction. The options were cashed out for a payment equal to the excess of the merger consideration of $72.00 over each option’s exercise price.
Avidity Biosciences, Inc. Chief Technical Officer Charles Calderaro III reported disposing of company equity in connection with the planned acquisition by Novartis AG. He surrendered 98,547 shares of Common Stock (including shares underlying previously reported restricted stock units) and 80,000 stock options to the issuer pursuant to a Merger Agreement dated October 25, 2025. The options were cashed out for the excess of the merger consideration of $72.00 per share over their exercise price, reflecting merger-related settlement rather than open-market trading.
Avidity Biosciences, Inc. notified the removal/withdrawal of its Common Stock from listing and registration on the Nasdaq Stock Market LLC.
The notice states Nasdaq and the issuer each complied with the applicable rules under 17 CFR 240.12d2-2 governing voluntary withdrawal and removal procedures.